Taigen Biopharmaceuticals Holdings Ltd (4157) - Net Assets
Based on the latest financial reports, Taigen Biopharmaceuticals Holdings Ltd (4157) has net assets worth NT$1.02 Billion TWD (≈ $32.21 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$1.06 Billion ≈ $33.40 Million USD) and total liabilities (NT$37.84 Million ≈ $1.19 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Taigen Biopharmaceuticals Holdings Ltd (4157) strategic investment index to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$1.02 Billion |
| % of Total Assets | 96.43% |
| Annual Growth Rate | N/A |
| 5-Year Change | -14.26% |
| 10-Year Change | 59.09% |
| Growth Volatility | 131.76 |
Taigen Biopharmaceuticals Holdings Ltd - Net Assets Trend (2010–2025)
This chart illustrates how Taigen Biopharmaceuticals Holdings Ltd's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see Taigen Biopharmaceuticals Holdings Ltd (4157) market capitalisation.
Annual Net Assets for Taigen Biopharmaceuticals Holdings Ltd (2010–2025)
The table below shows the annual net assets of Taigen Biopharmaceuticals Holdings Ltd from 2010 to 2025. Also explore Taigen Biopharmaceuticals Holdings Ltd equity growth rate to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | NT$1.07 Billion ≈ $33.86 Million |
-0.69% |
| 2024-12-31 | NT$1.08 Billion ≈ $34.10 Million |
-3.27% |
| 2023-12-31 | NT$1.12 Billion ≈ $35.25 Million |
+15.35% |
| 2022-12-31 | NT$970.03 Million ≈ $30.56 Million |
-22.63% |
| 2021-12-31 | NT$1.25 Billion ≈ $39.50 Million |
+183.52% |
| 2020-12-31 | NT$442.18 Million ≈ $13.93 Million |
-45.76% |
| 2019-12-31 | NT$815.18 Million ≈ $25.68 Million |
-25.44% |
| 2018-12-31 | NT$1.09 Billion ≈ $34.45 Million |
-23.25% |
| 2017-12-31 | NT$1.42 Billion ≈ $44.88 Million |
+110.84% |
| 2016-12-31 | NT$675.62 Million ≈ $21.29 Million |
+52.99% |
| 2015-12-31 | NT$441.60 Million ≈ $13.91 Million |
-48.18% |
| 2014-12-31 | NT$852.14 Million ≈ $26.85 Million |
+454.15% |
| 2013-12-31 | NT$153.77 Million ≈ $4.84 Million |
-58.75% |
| 2012-12-31 | NT$372.80 Million ≈ $11.75 Million |
-27.36% |
| 2011-12-31 | NT$513.21 Million ≈ $16.17 Million |
+111.96% |
| 2010-12-31 | NT$-4.29 Billion ≈ $-135.14 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Taigen Biopharmaceuticals Holdings Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 537652400000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | NT$589.18 Million | 54.81% |
| Other Components | NT$485.70 Million | 45.19% |
| Total Equity | NT$1.07 Billion | 100.00% |
Taigen Biopharmaceuticals Holdings Ltd Competitors by Market Cap
The table below lists competitors of Taigen Biopharmaceuticals Holdings Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
AIRO Group Holdings, Inc. Common Stock
NASDAQ:AIRO
|
$198.53 Million |
|
Superior Uniform Group Inc
NASDAQ:SGC
|
$198.55 Million |
|
CMC Corp
VN:CMG
|
$198.66 Million |
|
Hillgrove Resources Ltd
AU:HGO
|
$198.67 Million |
|
Solvar Ltd
AU:SVR
|
$198.45 Million |
|
NORTHERN OCEAN LTD.
F:4JO
|
$198.30 Million |
|
Taokaenoi Food & Marketing Public Company Limited
BK:TKN
|
$198.26 Million |
|
Plum Acquisition Corp. IV Class A Ordinary Shares
NASDAQ:PLMK
|
$198.24 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Taigen Biopharmaceuticals Holdings Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,082,326,000 to 1,074,877,000, a change of -7,449,000 (-0.7%).
- Net income of 45,178,000 contributed positively to equity growth.
- Share repurchases of 57,275,000 reduced equity.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$45.18 Million | +4.2% |
| Share Repurchases | NT$57.27 Million | -5.33% |
| Other Changes | NT$4.65 Million | +0.43% |
| Total Change | NT$- | -0.69% |
Book Value vs Market Value Analysis
This analysis compares Taigen Biopharmaceuticals Holdings Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.86x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2010-12-31 | NT$-7.60 | NT$8.85 | x |
| 2011-12-31 | NT$0.88 | NT$8.85 | x |
| 2012-12-31 | NT$0.63 | NT$8.85 | x |
| 2013-12-31 | NT$0.24 | NT$8.85 | x |
| 2014-12-31 | NT$1.22 | NT$8.85 | x |
| 2015-12-31 | NT$0.63 | NT$8.85 | x |
| 2016-12-31 | NT$0.95 | NT$8.85 | x |
| 2017-12-31 | NT$1.99 | NT$8.85 | x |
| 2018-12-31 | NT$1.53 | NT$8.85 | x |
| 2019-12-31 | NT$1.14 | NT$8.85 | x |
| 2020-12-31 | NT$0.62 | NT$8.85 | x |
| 2021-12-31 | NT$1.75 | NT$8.85 | x |
| 2022-12-31 | NT$1.35 | NT$8.85 | x |
| 2023-12-31 | NT$1.56 | NT$8.85 | x |
| 2024-12-31 | NT$1.51 | NT$8.85 | x |
| 2025-12-31 | NT$1.51 | NT$8.85 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Taigen Biopharmaceuticals Holdings Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 4.20%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 17.41%
- • Asset Turnover: 0.22x
- • Equity Multiplier: 1.09x
- Recent ROE (4.20%) is above the historical average (-39.55%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2010 | 0.00% | -15333.54% | 0.01x | 0.00x | NT$-1.86 Billion |
| 2011 | 8.35% | 18.98% | 0.37x | 1.19x | NT$-8.48 Million |
| 2012 | -125.64% | -1158.25% | 0.06x | 1.97x | NT$-505.68 Million |
| 2013 | -281.06% | -618.52% | 0.14x | 3.16x | NT$-447.57 Million |
| 2014 | -47.38% | -385.97% | 0.10x | 1.29x | NT$-488.93 Million |
| 2015 | -93.52% | -529.45% | 0.12x | 1.42x | NT$-457.15 Million |
| 2016 | -37.01% | -171.23% | 0.18x | 1.22x | NT$-317.60 Million |
| 2017 | 52.40% | 134.92% | 0.36x | 1.07x | NT$603.93 Million |
| 2018 | -31.39% | -1158.79% | 0.02x | 1.09x | NT$-452.54 Million |
| 2019 | -36.27% | -1455.57% | 0.02x | 1.16x | NT$-377.20 Million |
| 2020 | -91.55% | -1728.37% | 0.04x | 1.26x | NT$-449.04 Million |
| 2021 | 61.87% | 59.92% | 0.93x | 1.11x | NT$650.25 Million |
| 2022 | -24.45% | -654.61% | 0.03x | 1.08x | NT$-334.17 Million |
| 2023 | 12.22% | 111.04% | 0.10x | 1.10x | NT$24.84 Million |
| 2024 | -3.56% | -25.61% | 0.13x | 1.08x | NT$-146.82 Million |
| 2025 | 4.20% | 17.41% | 0.22x | 1.09x | NT$-62.31 Million |
Industry Comparison
This section compares Taigen Biopharmaceuticals Holdings Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,781,925,700
- Average return on equity (ROE) among peers: 7.78%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Taigen Biopharmaceuticals Holdings Ltd (4157) | NT$1.02 Billion | 0.00% | 0.04x | $198.48 Million |
| Apex Biotechnology Corp (1733) | $1.10 Billion | 27.61% | 0.18x | $95.41 Million |
| Sinphar Pharmaceutical Co Ltd (1734) | $3.63 Billion | 1.01% | 0.67x | $192.35 Million |
| Panion & BF Biotech Inc (1760) | $710.84 Million | 6.79% | 0.56x | $145.06 Million |
| Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) | $2.50 Billion | 21.29% | 0.26x | $81.67 Million |
| SYN-Tech Chem & Pharm Co Ltd (1777) | $2.32 Billion | 10.83% | 0.25x | $104.38 Million |
| Level Biotechnology (3118) | $513.75 Million | 9.23% | 0.46x | $31.54 Million |
| GenMont Biotech Inc (3164) | $1.37 Billion | 3.33% | 0.09x | $44.17 Million |
| Medigen Biotechnology (3176) | $3.66 Billion | 0.00% | 0.22x | $165.68 Million |
| Sagittarius Life Science (3205) | $419.76 Million | -11.56% | 0.24x | $99.91 Million |
| Genovate Biotechnology Co Ltd (4130) | $1.60 Billion | 9.31% | 0.28x | $115.03 Million |
About Taigen Biopharmaceuticals Holdings Ltd
TaiGen Biopharmaceuticals Holdings Limited, a pharmaceutical company, develops novel therapeutics for transformative diseases worldwide. The company develops Taigexyn (Nemonoxacin), a non-fluorinated quinolone antibiotic for the treatment of bacterial infections. Its product pipeline comprises Taigexyn, which is in phase II clinical trial for the treatment of community-acquired pneumonia/diabetic… Read more